T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.
Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, Eil R, Fioravanti J, Gattinoni L, Kochenderfer JN, Fry TJ, Aksoy BA, Hammerbacher JE, Cruz AC, Siegel RM, Restifo NP, Klebanoff CA.
Yamamoto TN, et al. Among authors: cruz ac.
J Clin Invest. 2019 Feb 25;129(4):1551-1565. doi: 10.1172/JCI121491. eCollection 2019 Feb 25.
J Clin Invest. 2019.
PMID: 30694219
Free PMC article.